



(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 487/04 (2006.01)
C07D 405/14 (2006.01) A61P 37/00 (2006.01)
C07D 413/14 (2006.01) A61K 31/55 (2006.01)
C07D 417/14 (2006.01)

(21) International Application Number:

PCT/US2014/063691

(22) International Filing Date:

3 November 2014 (03.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/900,465 6 November 2013 (06.11.2013) US


(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(72) Inventors: LUO, Guanglin; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). CHEN, Ling; c/o Bristol-Myers Squibb Com-
pany, 5 Research Parkway, Wallingford, Connecticut
06492 (US). DUBOWCHIK, Gene M.; c/o Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US). JACUTIN-PORTE, Swanee E.; c/o
Bristol-Myers Squibb Company, 5 Research Parkway,

Wallingford, Connecticut 06492 (US). VRUDHULA,
Vivekananda M.; 90 Blueberry Hill Reserve, Killing-
worth, Connecticut 06419 (US). PAN, Senliang; 30 Rim-
mon Road, Woodbridge, Connecticut 06525 (US).
SIVAPRAKASAM, Prasanna; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). MACOR, John E.; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(74) Agents: EPPERSON, James et al.; Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

[Continued on next page]

(54) Title: GSK-3 INHIBITORS



I

(57) Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.



TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*